This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage (EVAPROPEC)

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2016 by Centre Hospitalier Universitaire de Besancon
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Besancon Identifier:
First received: January 18, 2013
Last updated: March 29, 2016
Last verified: March 2016

Aneurysmal subarachnoid hemorrhage is a common and serious disease associated to a high rate of mortality and morbidity. Severe definitive neurological impairment can concern up to 30% of patients in relation with elevated intracranial pressure, hemorrhage recurrence and symptomatic cerebral arterial vasospasm. This latter complication is defined as a reversible reduction of cerebral artery's diameter occurring between the 4th and the 14th day after bleeding. Physiopathology is not well understood, but could involve endothelium, trough endothelial progenitor cells (EPC). Circulating EPC are bone marrow-derived cells with capacity of vasculogenesis and angiogenesis. EPC have been recognized playing a beneficial role in cardiovascular disease and ischemic stroke. EPC have never been studied in aneurysmal subarachnoid hemorrhage.

The primary objective of this study is to compare the number of circulating endothelial progenitor cells between patients with a good neurological outcome (defined as a glasgow outcome scale = 1 or 2) and patients with a poor neurological outcome (glasgow outcome scale = 3, 4 or 5).

Briefly, the number of circulating EPC will be measured at admission, and at day 3, 6, 10, 14, 21 in each consecutive patient suffering aneurysmal subarachnoid hemorrhage and hospitalized in Teaching Hospital of Besançon (France). The neurological outcome will be measured one year after subarachnoid hemorrhage.

Aneurysmal Subarachnoid Hemorrhage

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage (Evaluation de l'intérêt Pronostic Des progéniteurs endothéliaux Circulants Dans l'hémorragie Sous-arachnoïdienne Par Rupture d'anévrysme cérébral)

Resource links provided by NLM:

Further study details as provided by Centre Hospitalier Universitaire de Besancon:

Primary Outcome Measures:
  • endothelial progenitor cells count [ Time Frame: day 3 after bleeding ]

Secondary Outcome Measures:
  • Endothelial progenitor cells count [ Time Frame: day 0, 6, 10, 14, 21 after bleeding ]
  • Maximal amplitude of variation of EPC count [ Time Frame: 3 weeks after bleeding ]
  • Plasmatic brain natriuretic peptide [ Time Frame: day 0, 3, 6, 10, 14, 21 after bleeding ]

Other Outcome Measures:
  • Glasgow Outcome Scale [ Time Frame: One year after bleeding ]
  • Vasospasm occurence [ Time Frame: during the 3 weeks after bleeding ]

    Vasospasm will be defined as at less one segmental narrowing of a cerebral artery diagnosed on cerebral angiography (angio scanner, angio-MRI or 4 axes cerebral arteriography). Cerebral angiography will be done as necessary according to the occurence of the following situations

    • a clinical neurological deterioration unexplained by another cause
    • a mean arterial blood flow speed higher than 2 m/s assessed in cerebral arteries by transcranial doppler or a significant elevation of the mean arterial blood flow speed on two consecutive evaluations

Estimated Enrollment: 92
Study Start Date: March 2013
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Aneurysmal Subarachnoid Hemorrhage
Each consecutive patient suffering from aneurysmal subarachnoid hemorrhage


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Consecutive patients suffering from acute aneurysmal subarachnoid haemorrhage. .

Inclusion Criteria:

  • recent(< 24 h) aneurysmal subarachnoid hemorrhage
  • written informed consent obtained from the patient or from close relatives

Exclusion Criteria:

  • refusal to participate
  • Non-aneurysmal subarachnoid hemorrhage
  • aneurysmal subarachnoid hemorrhage with estimated date of bleeding > 24 h
  • Chronic heart failure
  • Chronic medication able to modify the plasmatic level of BNP
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01773200

Contact: Sébastien Pili-Floury, MD, PhD +33 3 81 66 85 79

CHRU de Besançon Recruiting
Besançon, France, 25000
Sponsors and Collaborators
Centre Hospitalier Universitaire de Besancon
Principal Investigator: Sébastien Pili-Floury, MD, PhD CHRU de Besançon
  More Information

Responsible Party: Centre Hospitalier Universitaire de Besancon Identifier: NCT01773200     History of Changes
Other Study ID Numbers: P/2012/153
Study First Received: January 18, 2013
Last Updated: March 29, 2016

Keywords provided by Centre Hospitalier Universitaire de Besancon:
endothelial progenitor cells
aneurysmal subarachnoid hemorrhage

Additional relevant MeSH terms:
Subarachnoid Hemorrhage
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on August 16, 2017